Brussels contacts fifth manufacturer over COVID-19 vaccine

25th August 2020

Plans for an initial purchase of 80 million doses

The European Commission has concluded talks with a fifth coronavirus vaccine manufacturer in its efforts to ensure that doses are rapidly available on the market.

A contract with US-based company Moderna, with which Brussels has just concluded exploratory talks, would provide for the possibility for all EU member states to purchase the vaccine and also to donate to lower and middle income countries or redirect to European countries, the Commission said.

Brussels plans to have a contractual framework in place for the initial purchase of 80 million doses on behalf of all EU member states, plus an option to purchase up to a further 80 million doses, to be supplied once a vaccine has proven to be safe and effective against COVID-19.

Intensive talks with other vaccine manufacturers continue. Apart from Moderna, the Commission has also concluded talks with Sanofi-GSK, Johnson & Johnson and CureVac. It has signed an advance purchase agreement with AstraZeneca.

“We invest in companies using diverse technologies to increase our chances to have vaccines that are safe and effective,” European Commission Ursula von der Leyen said.

Over 9,000 bedrooms and 24,000 available

31st July 2020

The Malta Chamber has always called for clear guidelines for businesses to follow, to ensure public ...

27th July 2020

The Malta Chamber is in active contact with players in the events and entertainment industries with ...

6th July 2020

By providing your insights about your business, we will be able to better design economic models whi...

Brussels contacts fifth manufacturer over COVID-19 vaccine